Ajaz Khan, MD
Hematology & Oncology · Zion, ILNPI 1043484736
Payments from drug & device makers
Across 35 payments — averaging $7307.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$189K
- Merck$60K
- AstraZeneca$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Fennec Pharmaceuticals, Inc.$2K
- Foundation Medicine, Inc.$229
- plus $810 from 9 others
What the payments were for
- Consulting fees$5,78083%
- Food & beverage$1,10516%
- Education$1112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $188,517 |
| Merck | 5 | $60,334 |
| AstraZeneca | 2 | $2,358 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,785 |
| Fennec Pharmaceuticals, Inc. | 3 | $1,715 |
| Foundation Medicine, Inc. | 1 | $229 |
| Lilly USA, LLC | 3 | $154 |
| Clovis Oncology, Inc. | 1 | $154 |
| Janssen Research & Development, LLC | 1 | $150 |
| Novartis | 8 | $136 |
| Gilead | 3 | $68 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Jazz Pharmaceuticals Inc. | 1 | $35 |
| Springworks Therapeutics, Inc. | 1 | $35 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALUNBRIG$1,785
- Pedmark$1,650
- FOUNDATIONONE CDX$229
How this compares
$255,748 in reported general payments places this provider in the 80th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 28 | $428,248 |
| XtandiEnzalutamide | 12 | $106,679 |
| EliquisApixaban | 14 | $10,022 |
| Anastrozole | 19 | $442 |
| Prochlorperazine Maleate | 22 | $362 |
| Tamsulosin Hcl | 30 | $314 |
| Letrozole | 15 | $291 |
| Levothyroxine Sodium | 48 | $259 |
| Dexamethasone | 14 | $251 |
| Ondansetron OdtOndansetron | 18 | $229 |
| Gabapentin | 16 | $171 |
| Ondansetron Hcl | 15 | $64 |
| Alprazolam | 14 | $55 |
| Prednisone | 17 | $37 |
| Pantoprazole Sodium | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Zion
- Walter StadlerZion$3.5M
- Tulio RodriguezZion$1.7M
- Richard SchilskyBurr Ridge$87.1M
- Edwin PosadasBurr Ridge$70.9M
- Oana DanciuChicago$23.2M
- Shuo MaChicago$20.5M
- Olwen HahnChicago$11.9M
- Christine BestvinaChicago$11.3M
- Russell SzmulewitzChicago$9.8M
- Randy SweisChicago$9.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.